תפריט ראשי עליון

תפריט עמוד

תוכן עניינים

​Publications

Medicinal Cannabis Research at Ichilov

1) Single center experience with medical cannabis in Gilles de la Tourette syndrome.
Thaler A1, Arad S2, Schleider LB3, Knaani J2, Taichman T2, Giladi N4, Gurevich T4. Parkinsonism Relat Disord. 2019 Apr;61:211-213.

2) Use of medical cannabis: perceptions of Israeli oncologists.
Mirelman D1, Waissengrin B1, Goldway N2, Sharon H3, Brill S4, Wolf I5..
Lancet Oncol. 2019 Apr;20(4):475-477. 

3) Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.
Sarid N, Zada M, Lev-Ran S, Yashphe E, Givon I, Barzilai M, Perry C, Avivi I, Wolf I.
Acta Haematol. 2018;140(4):194-202. doi: 10.1159/000493567. Epub 2018 Oct 19.

4) Single center experience with medical cannabis in Gilles de la Tourette syndrome.
Thaler A, Arad S, Schleider LB, Knaani J, Taichman T, Giladi N, Gurevich T.
Parkinsonism Relat Disord. 2019 Apr;61:211-213

5) Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity.
Weizman L, Dayan L, Brill S, Nahman-Averbuch H, Hendler T, Jacob G, Sharon H.
Neurology. 2018 Oct 2;91(14):e1285-e1294.

6) Personal experience and attitudes of pain medicine specialists in Israel regarding the medical use of cannabis for chronic pain.
Sharon H, Goldway N, Goor-Aryeh I, Eisenberg E, Brill S.
J Pain Res. 2018 Jul 31;11:1411-1419. doi: 10.2147/JPR.S159852. eCollection 2018.

7) European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management.
Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, Perrot S, Schäfer M, Wells C, Brill S. Eur J Pain. 2018 Oct;22(9):1547-1564.

8) Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
Hausman-Kedem M, Menascu S, Kramer U. Brain Dev. 2018 Aug;40(7):544-551.

9) Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic.
Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A.
Aust N Z J Psychiatry. 2004 Jan-Feb;38(1-2):42-6.

10) Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.
Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, Baruch Y, Djaldetti R, Giladi N, Gurevich T.
Clin Neuropharmacol. 2017 Nov/Dec;40(6):268-272.

11) Efficacy of Medical Cannabis for Treatment of Refractory Epilepsy in Children and Adolescents with Emphasis on the Israeli Experience.
Hausman-Kedem M, Kramer U. Isr Med Assoc J. 2017 Feb;19(2):76-78.

12) Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders.
Ablin JN, Elkayam O, Fitzcharles MA. Rambam Maimonides Med J. 2016 Apr 19;7(2). 

13) CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B. Seizure. 2016 Feb;35:41-4.

14) Medical use of cannabis products: Lessons to be learned from Israel and Canada.
Ablin J, Ste-Marie PA, Schäfer M, Häuser W, Fitzcharles MA. Schmerz. 2016 Feb;30(1):3-13.

15) Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience.
Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I. J Pain Symptom Manage. 2015 Feb;49(2):223-30.

16) Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic.
Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Aust N Z J Psychiatry. 2004 Jan-Feb;38(1-2):42-6.

17) Complementary Therapies in Inflammatory Bowel Diseases.
Yanai H, Salomon N, Lahat A. Curr Gastroenterol Rep. 2016 Dec;18(12):62. Review.

18) Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
Atsmon J, Heffetz D, Deutsch L, Deutsch F, Sacks H. Clin Pharmacol Drug Dev. 2018 Sep;7(7):751-758.

19) Problematic Use of Prescription Opioids and Medicinal Cannabis Among Patients Suffering from Chronic Pain. 
Feingold D, Goor-Aryeh I, Bril S, Delayahu Y, Lev-Ran S. Pain Med. 2017 Feb 1;18(2):294-306.

20) Pain in Extrapyramidal Neurodegenerative Diseases.
Yust-Katz S, Hershkovitz R, Gurevich T, Djaldetti R. Clin J Pain. 2017 Jul;33(7):635-639.

21) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Fitzcharles MA, Baerwald C, Ablin J, Häuser W.
Schmerz. 2016 Feb;30(1):47-61.

תפריט ניווט תחתון